S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
NASDAQ:ANEB

Anebulo Pharmaceuticals Stock Forecast, Price & News

$7.20
+0.02 (+0.28 %)
(As of 10/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.05
$7.20
50-Day Range
$6.55
$7.32
52-Week Range
$6.31
$9.33
Volume2,715 shs
Average Volume15,200 shs
Market Capitalization$168.08 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ANEB News and Ratings via Email

Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANEB
Employees
2
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.92 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$168.08 million
Next Earnings Date
12/22/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.03 out of 5 stars

Medical Sector

543rd out of 1,361 stocks

Pharmaceutical Preparations Industry

252nd out of 668 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Anebulo Pharmaceuticals (NASDAQ:ANEB) Frequently Asked Questions

Is Anebulo Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anebulo Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Anebulo Pharmaceuticals stock.
View analyst ratings for Anebulo Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Anebulo Pharmaceuticals?

Wall Street analysts have given Anebulo Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Anebulo Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals saw a decrease in short interest in September. As of September 30th, there was short interest totaling 5,600 shares, a decrease of 34.9% from the September 15th total of 8,600 shares. Based on an average daily trading volume, of 3,400 shares, the days-to-cover ratio is currently 1.6 days. Approximately 0.2% of the shares of the stock are short sold.
View Anebulo Pharmaceuticals' Short Interest
.

When is Anebulo Pharmaceuticals' next earnings date?

Anebulo Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, December 22nd 2021.
View our earnings forecast for Anebulo Pharmaceuticals
.

How were Anebulo Pharmaceuticals' earnings last quarter?

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) issued its quarterly earnings results on Tuesday, September, 21st. The company reported ($1.59) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $1.56.
View Anebulo Pharmaceuticals' earnings history
.

What price target have analysts set for ANEB?

1 brokers have issued twelve-month price targets for Anebulo Pharmaceuticals' shares. Their forecasts range from $15.00 to $15.00. On average, they anticipate Anebulo Pharmaceuticals' share price to reach $15.00 in the next twelve months. This suggests a possible upside of 108.3% from the stock's current price.
View analysts' price targets for Anebulo Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Anebulo Pharmaceuticals' key executives?

Anebulo Pharmaceuticals' management team includes the following people:
  • Dr. Joseph F. Lawler, Founder & Chairman (Age 48)
  • Dr. Daniel Schneeberger M.B.A., M.D., CEO & Director (Age 36)
  • Mr. Rex Merchant CFA, Chief Financial Officer (Age 61)
  • Dr. Linda Klumpers Ph.D., Chief Scientific Officer

When did Anebulo Pharmaceuticals IPO?

(ANEB) raised $21 million in an initial public offering on Friday, May 7th 2021. The company issued 3,000,000 shares at a price of $6.00-$8.00 per share. The Benchmark Company served as the underwriter for the IPO.

What is Anebulo Pharmaceuticals' stock symbol?

Anebulo Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANEB."

When does Anebulo Pharmaceuticals' lock-up period expire?

Anebulo Pharmaceuticals' lock-up period expires on Wednesday, November 3rd. Anebulo Pharmaceuticals had issued 3,000,000 shares in its initial public offering on May 7th. The total size of the offering was $21,000,000 based on an initial share price of $7.00. After the expiration of Anebulo Pharmaceuticals' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

How do I buy shares of Anebulo Pharmaceuticals?

Shares of ANEB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anebulo Pharmaceuticals' stock price today?

One share of ANEB stock can currently be purchased for approximately $7.20.

How much money does Anebulo Pharmaceuticals make?

Anebulo Pharmaceuticals has a market capitalization of $168.08 million.

How many employees does Anebulo Pharmaceuticals have?

Anebulo Pharmaceuticals employs 2 workers across the globe.

What is Anebulo Pharmaceuticals' official website?

The official website for Anebulo Pharmaceuticals is www.anebulo.com.

How can I contact Anebulo Pharmaceuticals?

The company can be reached via phone at 737-203-5270 or via email at [email protected].


This page was last updated on 10/18/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.